Jan 13, 2026 10:59AM Aquestive Therapeutics Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through the Firm's Investigation

Jan 9, 2026 07:02AM Aquestive receives FDA letter citing deficiencies in Anaphylm drug application

Nov 5, 2025 04:27PM Aquestive Therapeutics Inc. (AQST) Reports In-Line Q3 EPS

Oct 9, 2025 04:11AM Aquestive Therapeutics price target raised to $12 at Citizens on Anaphylm patents

Oct 8, 2025 07:00AM Aquestive Therapeutics receives patents for Anaphylm extending protection to 2037

Sep 4, 2025 07:00AM Aquestive says FDA won't require advisory meeting for Anaphylm drug

Aug 26, 2025 08:07AM Piper Sandler on Aquestive Therapeutics (AQST): 'Encouraging Feedback On Anaphylm'

Aug 19, 2025 07:01AM Cantor Fitzgerald Reiterates Overweight Rating on Aquestive Therapeutics (AQST)

Aug 14, 2025 06:01AM Aquestive secures $75 million funding from RTW for Anaphylm launch

Aug 11, 2025 04:26PM Aquestive Therapeutics Inc. (AQST) Tops Q2 EPS by 3c

Jul 22, 2025 08:53AM Aquestive Therapeutics promotes Korczynski to chief commercial officer

Jul 15, 2025 07:00AM Aquestive schedules Health Canada meeting for Anaphylm drug submission

Jun 17, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Aquestive Therapeutics (AQST)

Jun 17, 2025 05:15AM Increasing unusual call option volume: EWY GPN UMAC NVTS NXE SATS AQST

Jun 16, 2025 07:02AM Aquestive Therapeutics Inc. (AQST) Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions

Jun 2, 2025 08:50AM Oppenheimer Assumes Aquestive Therapeutics (AQST) at Outperform (correction)

May 13, 2025 03:26PM Raymond James Reiterates Outperform Rating on Aquestive Therapeutics (AQST)

May 13, 2025 07:37AM Aquestive Therapeutics Inc. (AQST) Misses Q1 EPS by 8c

Apr 1, 2025 07:00AM Aquestive Therapeutics Inc. (AQST) Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm Sublingual Film

Mar 10, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Aquestive Therapeutics (AQST)

Mar 5, 2025 04:34PM Aquestive Therapeutics Inc. (AQST) Misses Q4 EPS by 6c

Mar 3, 2025 01:09PM Leerink Partners Reiterates Outperform Rating on Aquestive Therapeutics (AQST)

Feb 19, 2025 01:08PM Leerink Partners Reiterates Outperform Rating on Aquestive Therapeutics (AQST), PT $13

Feb 18, 2025 04:23AM JMP Securities Reiterates Market Outperform Rating on Aquestive Therapeutics (AQST)

Dec 20, 2024 06:52AM H.C. Wainwright Reiterates Buy Rating on Aquestive Therapeutics (AQST)

Dec 19, 2024 08:02AM Aquestive Therapeutics (AQST) Receives FDA Orphan Drug Exclusivity for Libervant Buccal Film

Dec 17, 2024 06:31AM Cantor Fitzgerald Starts Aquestive Therapeutics (AQST) at Overweight

Dec 2, 2024 08:40AM Aquestive Therapeutics (AQST) PT Raised to $10 at Lake Street Capital Markets

Dec 2, 2024 08:02AM Aquestive Therapeutics Inc. (AQST) Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm Sublingual Film

Nov 6, 2024 09:24AM Aquestive Therapeutics (AQST) PT Raised to $10 at Lake Street Capital Markets

Nov 4, 2024 04:43PM Aquestive Therapeutics Inc. (AQST) Misses Q3 EPS by 1c

Oct 25, 2024 05:41AM Aquestive Therapeutics (AQST) PT Raised to $13 at Leerink Partners

Oct 24, 2024 08:03AM Aquestive Therapeutics Inc. (AQST) Announces Positive Topline Results from Oral Allergy Syndrome Challenge Study for Anaphylm Sublingual Film

Oct 8, 2024 08:10AM JMP Securities Reiterates Market Outperform Rating on Aquestive Therapeutics (AQST)

Sep 30, 2024 06:56AM Aquestive Therapeutics (AQST) PT Raised to $10 at H.C. Wainwright

Sep 27, 2024 08:32AM Aquestive Therapeutics (AQST) Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day

Aug 14, 2024 08:01AM Aquestive Therapeutics (AQST) Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm

Aug 6, 2024 04:46PM Aquestive Therapeutics Inc. (AQST) Tops Q2 EPS by 9c

Jul 25, 2024 08:02AM Aquestive Therapeutics (AQST) Reports Positive Topline Data for Anaphylm

Jun 25, 2024 08:50AM Aquestive Therapeutics (AQST) PT Lowered to $7 at Lake Street Capital Markets

Jun 25, 2024 08:00AM Aquestive Therapeutics (AQST) Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film